A meta-analysis including all studies on extended aromatase inhibition, which is soon expected to be done by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), will hopefully provide additional insight in which subgroups of patients benefit the most from extended aromatase inhibition. Here, CYP19A1 is linked to breast carcinoma.